中文版
|
English
Hotline：+86 2864841719
Enlai News
Enlai News
CONTACT US
联系我们
Outbound Sales&Marketing
 
Cynthia 
Tel: +86 2864841719 
Mobile: +86 17390183901 (English) 
Skype/Wechat:+86 18716376478
 
Mr. Yang  
Tel: +86 2884871826
Mobile: +86 13908183771   
Email: yangcx@enlaibio.com
 
Amy 
Tel： 028-84841969
Mobile：15884568590
QQ：551604319
Email：Amy@enlaibio.com

Bob
Tel：18980456393
Email：edison@enlaibio.com
QQ:3054240163
 
Daisy   
Tel：18314163848  
Email：daisy@enlaibio.com
QQ：2065506070

Enlai News Your current location: Homepage >Enlai News
请添加图片
First line treatment for chronic lymphocytic leukemia

As a first line treatment drugs for chronic lymphocytic leukemia, Ibrutinib improves survival compared with Ofatumumab in patients with previously treated Chronic Lymphocytic Leukemia.

Can you manufacture other peptides exclusively from your product list?2019-05-17

From Poverty to Harvard Postdoc2013-10-24

What are the acceptable payment methods?2019-05-05

Fingerprints Expose Chemical Identities 2019-01-04

2019 CPHI Shanghai Bio-Pharm Expo 2019-08-18

1/2 上一页 1 2 下一页

Outbound Sales&Marketing

Cynthia
Tel: +86 2864841719 (English)  
Mobile: +86 17390183901 (English)
Skype/Whatsapp/Wechat:+86 18716376478
Email: ycling@enlaibio.com

Mr.Yang 
Tel: +86 2884871826 
Mobile: +86 13908183771 
Email: yangcx@enlaibio.com
友情链接：

扫码二维码
打开官方网站

扫码二维码
关注官方微信
蜀ICP备10203788号